As reported on by Modern OB/GYN, the US Division of Well being and Human Companies (HHS) and the FDA introduced actions to revise security labeling for menopausal hormone remedy (MHT), often known as hormone alternative remedy (HRT). The FDA knowledgeable utility holders that up to date labeling will extra clearly describe profit and danger issues for systemic and native vaginal hormone merchandise.
MHT is permitted to deal with vasomotor signs (VMS), signs associated to vulvovaginal atrophy or genitourinary syndrome of menopause (GSM), and, for some merchandise, prevention of osteoporosis. In line with the FDA, the requested labeling adjustments comply with a complete evaluate of scientific literature, up to date drug utilization knowledge, public enter and the July 2025 FDA Professional Panel assembly.
The company reviewed knowledge revealed for the reason that authentic Ladies’s Well being Initiative (WHI) trials, which started within the Nineteen Nineties. WHI investigated estrogen plus progestin remedy in girls with a uterus and estrogen-alone remedy in girls with no uterus. Each trials have been stopped early within the 2000s due to reported will increase in breast most cancers, stroke and lack of proof of coronary artery illness prevention. Separate WHI research in older girls reported an elevated danger of possible dementia.
Class-wide boxed warnings have been added starting in 2003. In subsequent years, clinicians and affected person teams questioned the applicability of WHI findings to youthful menopausal girls for whom MHT is indicated. FDA drug utilization knowledge point out that MHT could also be underused: in 2020, roughly 2 million girls aged 46 to 65 years obtained prescriptions for systemic remedy, though the prevalence of average to extreme VMS is estimated at about 34% amongst girls aged 45 to 65 years.
The FDA famous that WHI members had a imply age of 63 years, which differs from the everyday age of menopause onset in the US (51 years). The company said that many ladies begin MHT between ages 45 and 55 years for symptom reduction, whereas WHI enrolled an older inhabitants with increased baseline dangers. The possible dementia findings have been additionally based mostly on girls aged 65 to 79 years, older than the inhabitants initiating MHT for VMS.
“The WHI research evaluated the security of oral conjugated equine estrogens + medroxyprogesterone acetate,” stated Lora Lansen, MD, chief medical officer at Elektra Well being, and a board and Menopause Society-certified household doctor. “That was the most well-liked and broadly accessible model of hormone remedy on the time. Newer therapies embody transdermal estradiol—which considerably diminishes the chance of VTE by avoiding first-pass hepatic metabolism—and oral micronized progesterone, which, not like artificial progestogens, has a seemingly impartial impact on breast tissue. It’s necessary to notice that we’d like extra knowledge to make up for the dearth of analysis on this area and till we higher perceive the total affect of MHT on breast most cancers danger, girls with a private historical past of breast most cancers stay ineligible for MHT.
Lansen added, “In reevaluating WHI knowledge, we’ve additionally discovered that timing issues. The danger of MHT-associated opposed outcomes remains to be thought of comparatively excessive for girls who begin MHT over 60 years of age and/or 10-plus years after their ultimate menstrual interval. Extra knowledge is required to find out whether or not MHT will be safely administered on this affected person inhabitants. For now, it’s endorsed that MHT begin <60 years outdated and <10 years after the ultimate menstrual interval. It may be continued for so long as there’s perceived profit.
Primarily based on its evaluation, the FDA requested a number of key labeling adjustments:
For all MHT merchandise (systemic and native vaginal):
- Take away language within the boxed warning associated to heart problems, breast most cancers and possible dementia.
- Take away language associated to endometrial most cancers apart from systemic estrogen-alone merchandise.
- Take away the advice to make use of the bottom efficient dose for the shortest period.
- Take away the possible dementia warning all through labeling.
For systemic merchandise:
- Add consideration of beginning remedy for average to extreme VMS in girls youthful than 60 years or inside 10 years of menopause onset.
- Add WHI knowledge for girls aged 50 to 59 years.
- Retain the boxed warning concerning endometrial most cancers for estrogen-alone merchandise.
- Retain data on heart problems and breast most cancers in labeling exterior the boxed warning.
For native vaginal estrogen merchandise:
- Condense security data and prioritize content material most related to native use.
At an HHS press convention asserting the broader coverage shift, Well being and Human Companies Secretary Robert F. Kennedy Jr. said, “At present, we’re standing up for each lady who has signs of menopause and is seeking to know her choices and obtain doubtlessly life-changing therapy.” He added, “We’re returning to evidence-based medication and giving girls management over their well being once more.”
FDA Commissioner Marty Makary, MD, MPH, stated, “Ladies and their physicians ought to make selections based mostly on knowledge, not concern.”
As estrogen and progesterone decline throughout menopause, hormone remedy can relieve signs corresponding to VMS, sleep disturbances and bone loss. Alicia Jackson, PhD, director of the Superior Analysis Tasks Company for Well being, stated, “Estrogen is a key hormone for girls’s well being. Each single a part of a lady’s physique depends upon estrogen to function at its greatest.”
The FDA additionally famous that randomized research present reductions in all-cause mortality and fractures amongst girls who provoke systemic hormone remedy inside 10 years of menopause or earlier than age 60 years. Up to date labeling is anticipated to replicate these issues.
Along with labeling adjustments, the FDA permitted 2 new therapies: a generic model of conjugated estrogens and a non-hormonal therapy for average to extreme VMS. The company said that the generic conjugated estrogen product is anticipated to enhance affordability and entry.
